Kodiak Sciences Inc
NASDAQ:KOD

  • LAST PRICE
    2.5950
  • TODAY'S CHANGE (%)
    -0.0150 (-0.5747%)
  • Bid / Lots
    2.5900/ 2
  • Ask / Lots
    2.6000/ 2
  • Open / Previous Close
    2.5600 / 2.6100
  • Day Range
    2.5080
    2.6250
  • 52 Week Range
    1.3700
    7.7700
  • Volume
    179,023

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

Charts

Price Comparison Graph. See accessible table below
Data delayed at least 15 minutes.

Biotechnology Industry Peers

CompanyMarket CapP/E Ratio (TTM)EPS Growth (5yr)
KOD
Kodiak Sciences Inc
137.3M
-0.7x
---
VIGL
Vigil Neuroscience Inc
134.8M
-1.6x
---
PDSB
PDS Biotechnology Corp
140.7M
-3.0x
---
ATYR
aTyr Pharma Inc
133.4M
-1.9x
---
ACTU
Actuate Therapeutics Inc
145.5M
0.0x
---
CNTX
Context Therapeutics Inc
147.0M
-1.8x
---
As of 2024-10-01

Company Information

Kodiak Sciences Inc. is a biopharmaceutical company. The Company has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) Platform, for retinal medicines. Its ABC Platform uses molecular engineering to merge the fields of protein-based and chemistry-based therapies. Its lead investigational medicine, tarcocimab, is a novel anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer conjugate under development for the treatment of high prevalence retinal vascular diseases, including diabetic retinopathy, the cause of blindness in working-age patients in the developed world, and wet age-related macular degeneration, the cause of blindness in elderly patients. Its second investigational medicine, KSI-501, is a bispecific antibody biopolymer conjugate targeting the pro-inflammatory cytokine interleukin-6 (IL-6) and VEGF. It is also developing a third investigational medicine, KSI-101, an unconjugated bispecific protein targeting IL-6 and VEGF.

Contact Information

Headquarters
1200 PAGE MILL RDPALO ALTO, CA, United States 94304
Phone
650-281-0850
Fax
302-636-5454

Executives

Chairman of the Board, Chief Executive Officer, Co-Founder
Victor Perlroth
Chief Financial Officer, Executive Vice President, Secretary
John Borgeson
Independent Director
Robert Profusek
Independent Director
Felix Baker
Independent Director
Charles Bancroft

Ratings

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

Reports

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals

Market Cap
$137.3M
Revenue (TTM)
$0.00
Shares Outstanding
52.6M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
2.34
EPS
$-3.77
Book Value
$5.06
P/E Ratio
-0.7x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Calendar

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.